Searchable abstracts of presentations at key conferences in endocrinology

ea0020s20.1 | Thyroid cancer | ECE2009

C Cell neoplasia

Elisei Rossella

Parafollicular C-Cells represent 1% of thyroid cells and differ from follicular cells for their origin from the neural crest. At variance with follicular cells, their growth and function are independent from thyrotropin stimulating hormone (TSH), they do not take up iodine and they produce and secrete calcitonin (CT) but not thyroglobulin. C-Cell Hyperplasia (CCH) is defined as an increased number of normal C-cells (i.e. 50 or more C-cells in at least one low-power field (100&...

ea0081oc11.6 | Oral Communications 11: Thyroid 2 | ECE2022

A new grading system for medullary thyroid cancer

Prete Alessandro , Gambale Carla , Torregrossa Liborio , Bottici Valeria , Cappagli Virginia , Basolo Fulvio , Elisei Rossella , Matrone Antonio

Introduction: medullary thyroid carcinoma (MTC) is a neuroendocrine thyroidal cancer. World Health Organization recognizes a grading system for almost all neuroendocrine tumors; however, a shared grading system for MTC is still lacking. We performed a clinical and pathological review of 257 MTCs to evaluate which histologic features have an impact on the disease specific survival and to propose a new grading system.Method: We retrospectively reviewed cli...

ea0081p638 | Endocrine-Related Cancer | ECE2022

TKI related adverse events in patients with progressive and metastatic thyroid carcinoma: a retrospective analysis of our experience with cabozantinib during EXAM and EXAMINER clinical trial

Cappagli Virginia , Bottici Valeria , Viola David , Agate Laura , Molinaro Eleonora , Elisei Rossella

Background: Vandetanib and Cabozantinib are the only two multitarget tyrosine kinase inhibitors approved for the management of metastatic and progressive medullary thyroid cancer. (MTC) Despite their efficacy in terms of progression free survival prolongation and overall response rate, the drug-related toxicity is still a clinical problem, impairing patient’s quality of life and the compliance to the treatment. We retrospectively evaluate the adverse events (AEs) occurred...

ea0081p472 | Thyroid | ECE2022

Cervical lymph nodes metastases in differentiated thyroid cancer: impact on clinical outcome

Gambale Carla , Matrone Antonio , Contartese Lea , Prete Alessandro , Viola David , Agate Laura , Molinaro Eleonora , Elisei Rossella

Background: Cervical lymph node metastases at histology are common findings in differentiated thyroid cancer (DTC); however, their impact on clinical outcome is debated.Material and method: 1332 DTC patients, performed the first 131 I treatment between January 2010 and September 2012 and were divided into 2 groups: absence (Nx/N0) or presence (N1) of lymph node metastases at histology. The latter group was further split in central compartment ...

ea0081p473 | Thyroid | ECE2022

Comparison of serum calcitonin and neck ultrasound sensitivities in identifying medullary thyroid carcinoma

Matrone Antonio , Gambale Carla , Prete Alessandro , Cappagli Virginia , Lorusso Loredana , Bottici Valeria , Vitti Paolo , Elisei Rossella

Background: Serum calcitonin (CT) is a very sensitive test for the diagnosis of medullary thyroid carcinoma (MTC). However, its routine dosage in patients with nodular thyroid disease is not recommended by all scientific societies. In addition, to optimize costs, it is only suggested in the case of suspicious nodules on ultrasound, indeterminate nodules at cytology or nodular goiter before surgery. The aim of the study is to evaluate the serum CT in a series of consecutive MTC...

ea0084op-03-12 | Oral Session 3: Advanced Thyroid Cancer | ETA2022

Clinicopathological and epidemiological features of thyroid cancer patients intended to initiate systemic therapy

Minaldi Elisa , Esposito Gerardo , Giani Carlotta , Valerio Laura , Agate Laura , Molinaro Eleonora , Elisei Rossella

Objectives: The majority of patients with differentiated thyroid carcinoma (TC) have an excellent prognosis, with a 5-year survival rate of 98.3%, and only rarely reaches an advanced stage of disease. The present study aims to identify the clinicopathological and epidemiological features at the time of diagnosis of a group of patients who required to be treated with systemic therapy with tyrosine-kinase inhibitors (TKI).Methods: We retrospectively evalua...

ea0084op-09-43 | Oral Session 9: Thyroid Cancer Clinical | ETA2022

Novel somatic mutations in sporadic MTC (spMTC); clinical utility of NGS in precision medicine

Simeakis George , Romei Cristina , Ciampi Raffaele , Ramone Teresa , Saltiki Katerina , Elisei Rossella , Alevizaki Maria

Objectives: Distant metastases in MTC adversely affect disease prognosis. Somatic mutations in spMTC as well as Variant Allele Frequency (VAF) have been related to tumor burden, disease course and the response to TKIs. The aim of this study is to report three cases of nucleotide (nt) insertions/deletions (indels) in the RET oncogene in relation to disease course/response to TKIs.Methods: Of 195 spMTC patients followed-up in Dept. Clinical Therap...

ea0084op-10-52 | Oral Session 10: Young Investigators / Clinical and Translational | ETA2022

Outcome of sporadic medullary thyroid cancer (MTC) patients with a biochemical persistent disease after initial treatment

Prete Alessandro , Gambale Carla , Bottici Valeria , Cappagli Virginia , Torregrossa Liborio , Elisei Rossella , Matrone Antonio

Introduction: MTC is a rare neuroendocrine tumor arising from thyroid parafollicular cells. After initial treatment, patients should be divided according to their clinical status in cured, biochemical persistence (BIO) and structural persistence (STR) of the disease. Concerning BIO patients less is known about the structural disease appearance rate and the time elapsed between the first evaluation after surgery and the appearance of structural disease.Me...

ea0084ps1-03-22 | Thyroid Cancer CLINICAL 1 | ETA2022

Low risk differentiated thyroid carcinoma (DTC) can be safely treated with thyroidectomy alone: real-life experience in a medium-long term follow-up

Faranda Alessio , Gambale Carla , Prete Alessandro , Contartese Lea , Molinaro Eleonora , Elisei Rossella , Matrone Antonio

Background: Since 2006 according to the European consensus for the management of patients with DTC, in tumors ≤ 1 cm, treatment with thyroidectomy alone without 131I treatment was suggested. Therefore, in our institution, we applied this suggestion in clinical practice, although prospective studies were not still available. Aim of this study is to evaluate the rate of the events occurring in a medium-long term follow-up.Patients and Meth...

ea0084ps2-07-62 | Graves’ Disease 1 | ETA2022

Multifocality in sporadic and familiar medullary thyroid cancer: analysis of prevalence and possible predictive roles

Cappagli Virginia , Bottici Valeria , Agate Laura , Molinaro Eleonora , Torregrossa Liborio , Elisei Rossella

Aims: Surgery is the only curative treatment for medullary thyroid cancer (MTC) patients and the gold standard practice is still represented by total thyroidectomy and prophylactic central neck compartment lymphnode dissection. As it happened for differentiated thyroid cancer, in the last years some authors proposed less aggressive and extent surgical modality as hemithyroidectomy and ipsilateral neck compartment dissection in unilateral and solitary sporadic MTC cases. Few st...